Previous 10 | Next 10 |
home / stock / lly / lly articles
A growing number of U.S. adolescents, facing record rates of pediatric obesity, are reportedly turning to Novo Nordisk A/S’s (NYSE:...
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 31.12% on an annualized basis producing an average annual return of 43.4%...
Jim Cramer, the host of CNBC’s “Mad Money,” has issued a warning to investors about the potential impact of weight loss drugs, su...
In support of expectations for Eli Lilly And Company’s (NYSE:LLY) tripeptide, BMO Capital Markets is tracking weekly Mounjaro, Zepbound, GL...
The unprecedented demand for weight loss drugs, including Novo Nordisk A/S’s (NYSE:NVO) Wegovy and Eli Lilly And Co’s&nb...
Tesla‘s (NASDAQ:TSLA) standing within the Magnificent Seven is in question. What Happened: The Austin, Texas-based electric vehicle (EV) com...
Jim Cramer, the host of CNBC’s “Mad Money,” has suggested that investors should look beyond the Magnificent Seven tech stocks for...
Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares are trading higher by 44.8% to $4.52 during Thursday’s session after the company announced tha...
Since Monday, Eli Lilly And Co (NYSE:LLY) shares have gained 8%, closing at $724.85 on Wednesday, sending the market capitalization to a ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...